Life sciences · Journal article
Cancer Immunology Immunotherapy · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Tissue-resident memory T (T RM ) cells represent a specialized subset of memory T cells defined by their long-term residency in peripheral non-lymphoid tissues, where they provide frontline immune surveillance at barrier sites such as the skin, intestines, lungs, and liver. Accumulating evidence has identified CD69 + CD103 + tumor-infiltrating lymphocytes exhibiting canonical T RM phenotypes across diverse cancers, where their abundance and functional states have been linked to anti-tumor immunity and predictors of favorable clinical outcomes. In this review, we synthesize current knowledge on T RM biology with a focus on their roles in cancer immunology. We first delineate core phenotypic markers and trace the differentiation trajectory of naïve T cells into T RM cells, highlighting tissue-specific developmental pathways. We then integrate molecular mechanisms, including transcription factor and epigenetic networks, cytokine cues, metabolic reprogramming toward lipid oxidation, and multicellular crosstalk, that collectively enforce T RM residency and function within the tumor microenvironment. Recognizing the heterogeneity of tumor-associated T RM -like TILs, we discuss their abundance, phenotypic features, and functional states, while examining their relationships with bystander and exhausted T cell populations across cancers. Finally, we evaluate the translational potential of T RM cells as predictive biomarkers for immune checkpoint blockade and as engineering targets for next-generation adoptive cell therapies and cancer vaccines. Collectively, this review offers a timely, mechanism-to-bedside framework for understanding how T RM cells bridge tissue immunity and cancer immunotherapy.